Current Report Filing (8-k)
December 10 2020 - 06:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 9, 2020
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
Delaware |
|
0-5286 |
|
38-0715562 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
2700 West Front Street |
|
28677 |
Statesville, North Carolina
(Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area
code: 704-873-7202
N/A
(Former name or former address, if changed since
last report.)
Securities registered pursuant to
Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $2.50 par
value |
|
KEQU |
|
NASDAQ Global Market |
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 |
Results of Operations and Financial
Condition
|
On December 9, 2020, Kewaunee Scientific Corporation (the
“Company”) issued a press release announcing its financial results
for the second quarter, ended October 31, 2020, of fiscal year
2021. A copy of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
The Company is making reference to non-GAAP financial information in the
press release. A reconciliation of these non-GAAP financial measures is
contained in the attached press release.
Item 9.01 |
Financial Statements and Exhibits
|
(d) Exhibits:
In accordance with General Instruction B.2 of Form 8-K, the information in this Current
Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of
that section, and shall not be incorporated by reference into any
registration statement or other document filed under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
Signature
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
(Registrant) |
|
|
|
|
Kewaunee Scientific
Corporation |
|
|
|
Date: December 9, 2020
|
|
|
|
/s/ Donald T. Gardner III
|
|
|
|
|
Donald T. Gardner III |
|
|
|
|
Vice President, Finance and Chief Financial
Officer |